Are We Overradiating Patients with Irritable Bowel Syndrome?
Cancer
Diagnostic imaging
Irritable bowel syndrome
Medical radiation
Journal
Inflammatory intestinal diseases
ISSN: 2296-9365
Titre abrégé: Inflamm Intest Dis
Pays: Switzerland
ID NLM: 101677990
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
23
06
2020
accepted:
24
08
2020
entrez:
14
4
2021
pubmed:
15
4
2021
medline:
15
4
2021
Statut:
ppublish
Résumé
Protracted exposures to small doses of radiation, even cumulative effective doses (CED) as low as 50-100 mSv, may increase the risk for malignancy. Medical radiation exposure has not been rigorously examined for patients with irritable bowel syndrome (IBS). We examined medical radiation exposure in patients with IBS at a tertiary care center in the USA. Patients diagnosed with IBS at our institute from 2009 to 2018 were included in a retrospective cohort study. Medical charts were examined to calculate total and annual CED. 221 patients were included; mean CED was 40.32 mSv (SD: 54.36). Fifty-nine participants (26.7%) received >50 mSv of CED with 27 participants (12.2%) exceeding 100 mSv. Conventional imaging, nuclear medicine, and fluoroscopy accounted for 74.08, 12.93, and 12.98% of total CED, respectively. CT scans contributed to 66.61% of total CED. Outpatient orders accounted for 37.96% of total CED, while 31.4% of total CED was ordered in the emergency department. Population-specific high total CED was calculated as 105.65 mSv. Multivariable binomial logistic regression model found that comorbid anxiety, chronic pain medication use, and diarrhea-predominant IBS were independently positively associated with population-specific high CED exposure. No significant temporal trend in peri-diagnostic mean CED was found. Patients with IBS receive high amounts of medical radiation, with 1 in 4 patients reaching at-risk levels of 50 mSv or more. Usage of pain medication at home, comorbid anxiety, and IBS-D are independently linked to an increased risk of high CED.
Identifiants
pubmed: 33850837
doi: 10.1159/000511105
pii: iid-0006-0032
pmc: PMC8015257
doi:
Types de publication
Journal Article
Langues
eng
Pagination
32-37Subventions
Organisme : NIGMS NIH HHS
ID : U54 GM104942
Pays : United States
Informations de copyright
Copyright © 2020 by S. Karger AG, Basel.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to disclose.
Références
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Scand J Gastroenterol. 2017 Mar;52(3):300-305
pubmed: 27832710
Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):13761-6
pubmed: 14610281
World J Gastroenterol. 2016 Feb 21;22(7):2165-78
pubmed: 26900282
Clin Gastroenterol Hepatol. 2012 Mar;10(3):259-65
pubmed: 22083022
World J Gastroenterol. 2014 May 28;20(20):6024-30
pubmed: 24876725
Abdom Radiol (NY). 2016 Jul;41(7):1363-9
pubmed: 26814500
Lancet. 2004 Jan 31;363(9406):345-51
pubmed: 15070562
Aliment Pharmacol Ther. 2007 Oct 1;26(7):1019-24
pubmed: 17877508
J Radiol Prot. 2009 Jun;29(2A):A43-59
pubmed: 19454804
Radiology. 2008 Jul;248(1):254-63
pubmed: 18566177
Radiat Res. 2007 Apr;167(4):396-416
pubmed: 17388693
Am J Gastroenterol. 2003 Mar;98(3):600-7
pubmed: 12650794
Fam Pract. 2005 Oct;22(5):474-7
pubmed: 15964875